• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC, 1994.
  • 2
    Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy. J. Am. Acad. Child Adolesc. Psychiatry 1989; 28: 777784.
  • 3
    Adler LA, Resnick S, Kunz M, Devinsky O. Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol. Bull. 1995; 31: 785788.
  • 4
    Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH. An open label trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol. 1995; 31: 779783.
  • 5
    Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit hyperactivity disorder: An open clinical trial. J. Clin. Psychiatry 1997; 58: 178179.
  • 6
    Upadhyaya HP, Brady KT, Sethurraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocain abuse and attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychopharmacol. 2001; 21: 116118.
  • 7
    Olvera RL, Pliska SR, Luch J, Tatum R. An open clinical trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescent. J. Child Adolesc. Psychopharmacol. 1996; 6: 241.
  • 8
    Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating Scales. J. Abnorm. Child Psychol. 1978; 6: 221236.
  • 9
    Campbell M, Palij M. Clinical Global Improvement Scale. Psychopharmacol. Bull. 1985; 21: 839848
  • 10
    Saletu B, Grunberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophiology. Br. J. Clin. Pharmacol. 1992; 33: 589601.